# Studies on the table

> The Good Peptides study shelf — The Good Peptides reading list: thymosin alpha-1 cell experiments, cancer trials and hepatitis comparisons.

**Reading list**

The cell experiments explain my interest in restraint. The human trials make the judgment harder. Both are here.

## Cells and tissue effects

Start with the [viral and bacterial stimulus comparison](https://pubmed.ncbi.nlm.nih.gov/26096650/). Beside it sit the [regulatory B-cell experiment](https://pubmed.ncbi.nlm.nih.gov/28273784/), the [bone-marrow-derived cell study of IDO](https://pubmed.ncbi.nlm.nih.gov/21575365/), and the [mouse study of intestinal toxicity during CTLA-4 blockade](https://pubmed.ncbi.nlm.nih.gov/32817121/).

## Cancer trials and synthesis

The [randomised metastatic melanoma study](https://pubmed.ncbi.nlm.nih.gov/20194853/) supplies the tumour-response and numerical survival findings. The [Cochrane review](https://pubmed.ncbi.nlm.nih.gov/21328265/) examines the wider trial record; the [lung-cancer phase 2 study](https://pubmed.ncbi.nlm.nih.gov/35870709/) follows radiation pneumonitis using historical controls.

## Hepatitis comparisons

The selection includes the [entecavir combination meta-analysis in HBV-related cirrhosis](https://pubmed.ncbi.nlm.nih.gov/33076834/), the [peginterferon comparison in hepatitis B](https://pubmed.ncbi.nlm.nih.gov/22726105/), and the [hepatitis C trial with different overall and completer results](https://pubmed.ncbi.nlm.nih.gov/22233415/). For the molecule itself, the [precursor-cleavage study](https://pubmed.ncbi.nlm.nih.gov/24288480/) describes generating mature thymosin alpha-1 from prothymosin alpha.

## References

[1] Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists https://pubmed.ncbi.nlm.nih.gov/26096650/
[2] Thymosin-α1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients https://pubmed.ncbi.nlm.nih.gov/28273784/
[3] [An experimental study on the regulation of bone marrow-derived mesenchymal stem cells through indoleamine 2,3-dioxygenase signaling pathway by thymosin α1 for improving the immunosuppression mediated by T cell] https://pubmed.ncbi.nlm.nih.gov/21575365/
[4] Thymosin α1 protects from CTLA-4 intestinal immunopathology https://pubmed.ncbi.nlm.nih.gov/32817121/
[5] Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma https://pubmed.ncbi.nlm.nih.gov/20194853/
[6] Thymic peptides for treatment of cancer patients https://pubmed.ncbi.nlm.nih.gov/21328265/
[7] The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis https://pubmed.ncbi.nlm.nih.gov/33076834/
[8] Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study https://pubmed.ncbi.nlm.nih.gov/22726105/
[9] Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? https://pubmed.ncbi.nlm.nih.gov/22233415/
[10] Generation of mature Nα-terminal acetylated thymosin α 1 by cleavage of recombinant prothymosin α https://pubmed.ncbi.nlm.nih.gov/24288480/
[11] Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043) https://pubmed.ncbi.nlm.nih.gov/35870709/

---

I interrogate immune stimulation and restraint at The Good Peptides, an editorial research site whose essays cannot provide medical advice or decide anyone’s treatment.